US/UK/Canada

Share

Contacts

  • Orexo
    Box 303 751 05 Uppsala
    +46 (0)18 780 88 00
    +46 (0)18 780 88 88
    http://www.orexo.com

    • Quotes

    With the acquisition of the rights to two digital health products from GAIA and the appointment of Dennis, a thought leader in the digital health industry in the US, we are well positioned to lead this development within the complementary disease areas of our pharmaceutical business.
    Nikolaj Sørensen, President and CEO
    Our strategy is to focus on solutions with scientifically proven therapeutic effect which will benefit the healthcare system as a whole and more importantly patients.
    Nikolaj Sørensen, CEO, about Digital Therapies
    I am convinced that DTx will become an integral and natural part of addiction treatment in the future. This digital therapy for OUD patients is perfectly positioned with Orexo’s competences and commercial organization in the US.
    Nikolaj Sørensen, President and CEO
    Mundipharma Australia has been a good partner in the approval process and we are confident that their experience and infrastructure will create a strong foundation for a successful launch of Zubsolv®
    Nikolaj Sørensen, President and CEO
    Pick a time period -
    Tags ( Active)

    Orexo AB focuses its business and reduces costs

    Uppsala, Sweden - March 6, 2012 - Orexo AB is focusing its development activities to the three proprietary programs OX219, OX51 and OX27. The total requirement for resources will thereby be reduced with up to 35 full time employees.The personnel reduction, which will have full effect in 2013, is expected to lower the costs by a total of SEK 30 million annually. Negotiations with trade union representatives will commence immediately. The reduction in personnel is expected to be completed during the second quarter of 2012."The focus of our business activities will now be fully in line

    Orexo announces successful completion of rights issue providing gross proceeds of about SEK 250 million

    Read more about Orexo Rights Issue at:http://www.orexo.com/en/Investor-Relations/Rights-issue---Important-Information/ For further information, contact:Anders Lundström, President and CEO of OrexoTel: +46 (0)70-667 22 66E-mail: anders.lundstrom@orexo.com About OrexoOrexo is a pharmaceutical company focusing on developing treatments for pain and inflammation. The company has four commercialized products, several projects developed in partnership as well as three proprietary development programs. Orexo’s registered products are Abstral® for the treatment of break through

    Orexo announces successful completion of the first clinical trial in OX51

    Uppsala, Sweden, March 31, 2011 - Orexo AB (STO: ORX) announces the positive outcome following completion of the initial pharmacokinetic trial in the OX51 project. The project is aimed at developing a sublingual dosage form tailored to treat acute intensive pain episodes in relation to care-related diagnostic or therapeutic procedures for patients whom are not receiving sufficient pain relief. Orexo plans to enter the next stage of development during the second half of 2011 following discussions with regulatory authorities. Orexo currently has 3 fully owned programs (including OX51)

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media